Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Convertible Debt (2018 - 2024)

Abvc Biopharma (ABVC) has disclosed Convertible Debt for 5 consecutive years, with $872336.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Convertible Debt rose 2661.69% year-over-year to $872336.0, compared with a TTM value of $872336.0 through Mar 2024, up 2661.69%, and an annual FY2023 reading of $886522.0, changed N/A over the prior year.
  • Convertible Debt was $872336.0 for Q1 2024 at Abvc Biopharma, down from $886522.0 in the prior quarter.
  • Across five years, Convertible Debt topped out at $3.3 million in Q2 2023 and bottomed at $31587.0 in Q1 2023.
  • Average Convertible Debt over 4 years is $1.8 million, with a median of $2.1 million recorded in 2020.
  • Peak annual rise in Convertible Debt hit 2661.69% in 2024, while the deepest fall reached 2661.69% in 2024.
  • Year by year, Convertible Debt stood at $2.5 million in 2020, then changed by 0.0% to $2.5 million in 2021, then tumbled by 64.54% to $886522.0 in 2023, then decreased by 1.6% to $872336.0 in 2024.
  • Business Quant data shows Convertible Debt for ABVC at $872336.0 in Q1 2024, $886522.0 in Q4 2023, and $1.7 million in Q3 2023.